The Indian Hotels Co. has drawn mixed reactions from analysts following its fourth quarter results, with Macquarie and Morgan Stanley offering contrasting outlooks on the stock. While both recognise the underlying strength in revenue performance, differences emerge over profitability and future growth projections.
Macquarie has maintained a 'neutral' rating and cut its target price to Rs 820 from Rs 840. The brokerage highlighted that the company delivered a revenue beat but fell short on Ebitda due to higher-than-expected employee expenses, which were 8% above estimates. This led to margin compression in the quarter.
Additionally, management reduced the financial year 2026/27 pipeline by around 10% from earlier guidance. Macquarie sees this as a signal of moderated growth expectations and has lowered its fiscal 2026-28 earnings per share estimates by 8–9%, due to reduced Ebitda and PAT margin projections.
In contrast, Morgan Stanley remains bullish, reaffirming its 'overweight' rating with a target price of Rs 864. It noted strong demand from business travel and major events such as the Mahakumbh festival and Coldplay concerts, which contributed meaningfully to hotel occupancy and revenue per available room growth. Morgan Stanley sees this trend continuing and was encouraged by management’s reaffirmation of a double-digit revenue growth target for financial year 2026.
The company’s balance sheet remains robust, with a net cash position of Rs 2,850 crore, and return on capital employed for fiscal 2025 improved to 17.3% from 15.1% in FY24.
Both brokerages acknowledged the strength in hotel segment revenue, though Macquarie flagged a miss in TajSATS performance due to changes in contract terms, which affected Ebitda margins.
While Macquarie remains cautious on cost pressures and future project visibility, Morgan Stanley is more focused on the strong demand outlook, ongoing capex in greenfield and renovation projects, and favourable trends in domestic travel.
Macquarie urges caution due to margin pressure and a trimmed project pipeline, while Morgan Stanley maintains a more optimistic view, driven by demand momentum and a positive management outlook.
RECOMMENDED FOR YOU

HAL Q1 Review: Can Order Execution Keep Up The Momentum? Brokerages Weigh In


Titan Q1 Review: Brokerages Remain Bullish, Citi And Jefferies Hike Target Price


Container Corp Q1 Review: Jefferies Cuts Target Price As Weak Volume Growth Weigh On Operating Profit


M&M Q1 Review: Analysts See Rising Commodity Prices To Weigh
